顺铂、安吖啶和丙脒腙用于难治性非霍奇金淋巴瘤的挽救治疗：西南肿瘤协作组的一项初步研究
Salvage treatment of unfavorable non-Hodgkin's lymphoma with cisplatin, amsacrine, and mitoguazone: a Southwest Oncology Group Pilot Study.
作者信息
Dana B W, Jones S E, Coltman C, Stuckey W J
出版信息
Cancer Treat Rep. 1986 Feb;70(2):291-2.
We tested the combination of cisplatin, amsacrine, and mitoguazone as salvage treatment for patients with advanced unfavorable non-Hodgkin's lymphomas. An objective response rate of 43% was noted in 30 evaluable patients, but all responses were partial and the median duration of response was only 2 months. Toxicity included life-threatening and fatal leukopenia and severe gastrointestinal intolerance. We conclude that this combination chemotherapy regimen is not a valuable salvage treatment for patients with non-Hodgkin's lymphoma.
我们测试了顺铂、安吖啶和丙脒腙联合用药作为晚期进展性非霍奇金淋巴瘤患者挽救治疗的效果。30例可评估患者的客观缓解率为43%，但所有缓解均为部分缓解，缓解持续时间中位数仅为2个月。毒性反应包括危及生命和致命的白细胞减少以及严重的胃肠道不耐受。我们得出结论，这种联合化疗方案对非霍奇金淋巴瘤患者而言并非有效的挽救治疗方法。
Zotero 插件